The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The impact of high-dose melphalan on myeloma-related mutations & risk level
Nathan Sweeney
• 17 May 2022
Nathan Sweeney, PhD, HealthTree, Lehi, UT, briefly discusses a study which investigated whether receiving high-dose melphalan would increase mutation burden and risk level in myeloma patients. Dr Sweeney discusses some results from this study and the impact of both high-dose melphalan and standard chemotherapy on disease burden. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
